Stockscreener 앱 받기
33.24
0.45%
0.15
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance UK
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next - TechStock²
Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open - TechStock²
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% – Time to Sell? - Defense World
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus - TechStock²
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Trend Recap: What makes Spyre Therapeutics Inc. stock attractive to growth fundsJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Why Spyre Therapeutics Inc. stock is recommended by analystsJuly 2025 Chart Watch & Safe Entry Momentum Stock Tips - Улправда
Will Spyre Therapeutics Inc. stock deliver shareholder value2025 Stock Rankings & Momentum Based Trading Ideas - Улправда
How geopolitical tensions affect Spyre Therapeutics Inc. stock2025 Biggest Moves & Technical Entry and Exit Tips - Улправда
How Spyre Therapeutics Inc. stock responds to policy changesSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho - MarketBeat
Citigroup Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Mizuho Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target - marketscreener.com
Mizuho Initiates Coverage on Spyre Therapeutics (SYRE) with 'Out - GuruFocus
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $52.33 - Defense World
Citigroup Initiates Coverage of Spyre Therapeutics (SYRE) with Buy Recommendation - Nasdaq
Mizuho initiates Spyre Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
SYRE: Citigroup Initiates Coverage with a 'Buy' Rating and $64 P - GuruFocus
4.73%
0.92%
자본화:
|
볼륨(24시간):